MannKind is trading 5.6% down at $3.73, with no clear company-specific announcement or same-day catalyst identified in the available news search. - Recent coverage discussed the prior rally and the Delaware ruling’s potential benefit to MannKind’s Tyvaso DPI royalties; neither explains today’s decline. - The broader market is sharply higher after weak employment data eased rate-hike concerns, but available evidence does not support linking MannKind’s decline to that move. - The pullback follows a 16.77% gain on September 30 and a further 1.28% rise on October 1.